Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: GLM004
MIFTS: 52

Gliomatosis Cerebri

Categories: Cancer diseases, Neuronal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Gliomatosis Cerebri

About this section

MalaCards integrated aliases for Gliomatosis Cerebri:

Name: Gliomatosis Cerebri 12 73 20 58 54 15 70
Neoplasms, Neuroepithelial 44
Astrocytosis Cerebri 12

Characteristics:

Orphanet epidemiological data:

58
gliomatosis cerebri
Inheritance: Not applicable; Age of onset: Adult;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 33
Orphanet: 58  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:6128
MeSH 44 D018302
NCIt 50 C4318
SNOMED-CT 67 26138003
ICD10 via Orphanet 33 C71.0
UMLS via Orphanet 71 C0334576
Orphanet 58 ORPHA251582
UMLS 70 C0334576
Sources

Summaries for Gliomatosis Cerebri

About this section
GARD : 20 Gliomatosis cerebri is a type of malignant (cancerous) brain tumor called a glioblastoma that develops from a specific type of brain cell called an astrocyte. It involves at least three sections (lobes) within the main part of the brain ( cerebrum ). It may also affect both sides of the cerebrum as well as the nerve cells within the brain ( grey matter ). There are two types of gliomatosis cerebri. Type 1 (classic form) is characterized by scattered and widespread tumor cells and no apparent mass or tumor, while type 2 has similar characteristics in addition to a detectable mass or tumor. Signs and symptoms of gliomatosis cerebri may include personality changes, memory disturbance, headaches, and seizures. Because this type of cancer can be found in many areas of the brain, it can be challenging to treat. Treatment might include surgery to remove areas of the brain affected (when possible), radiation therapy, and chemotherapy.

MalaCards based summary : Gliomatosis Cerebri, also known as neoplasms, neuroepithelial, is related to low-grade astrocytoma and high-grade astrocytoma, and has symptoms including seizures, headache and sensory manifestations. An important gene associated with Gliomatosis Cerebri is GFAP (Glial Fibrillary Acidic Protein), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Pharmaceutical Solutions and Psychotropic Drugs have been mentioned in the context of this disorder. Affiliated tissues include brain, eye and spinal cord, and related phenotypes are Decreased Hepatitis C Virus pseudoparticles (HCVpp; H77; genotype 1a) infection and immune system

Disease Ontology : 12 A brain cancer that is characterized by a pattern of diffuse infiltration of the brain that affect various areas of the cerebral lobes and has material basis in abnormally proliferating cells, derives from glial cells.

Wikipedia : 73 Gliomatosis cerebri is a rare primary brain tumor. It is commonly characterized by diffuse infiltration... more...

Sources

Related Diseases for Gliomatosis Cerebri

About this section

Diseases related to Gliomatosis Cerebri via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 449)
# Related Disease Score Top Affiliating Genes
1 low-grade astrocytoma 30.8 TP53 IDH1 CDKN2A
2 high-grade astrocytoma 30.4 TP53 PTEN IDH1
3 hydrocephalus 30.2 TP53 SYP PTEN NES GFAP
4 gemistocytic astrocytoma 30.2 TP53 PTEN IDH1 GFAP
5 diffuse astrocytoma 29.8 TP53 LUC7L2 IDH1 GFAP EGFR BRAF
6 oligodendroglioma 29.6 TP53 SYP PTEN MDM2 IDH1 GFAP
7 glioma 29.6 TP53 PTEN MDM2 IDH1 EGFR CDKN2A
8 malignant astrocytoma 29.5 TP53 PTEN NES MDM2 IDH1 GFAP
9 adenoma 29.5 TP53 SYP CDKN2A BRAF
10 central nervous system cancer 29.4 TP53 SYP PTEN NES IDH1 GFAP
11 high grade glioma 29.3 TP53 PTEN NES IDH1 GFAP EGFR
12 anaplastic astrocytoma 29.0 TP53 RB1 PTEN NES MDM2 IDH1
13 glioblastoma 28.8 TP53 RB1 PTEN NES MDM2 IDH1
14 pilocytic astrocytoma 28.6 TP53 SYP PTEN NES IDH1 GFAP
15 medulloblastoma 28.2 TP53 SYP RB1 PTEN NES MDM2
16 glioma susceptibility 1 10.8
17 glial tumor 10.6
18 intracranial hypertension 10.5
19 rare tumor 10.5
20 encephalitis 10.5
21 ataxia and polyneuropathy, adult-onset 10.4
22 urethra transitional cell carcinoma 10.4 TP53 GFAP
23 central nervous system immature teratoma 10.4 NES GFAP
24 anaplastic ganglioglioma 10.4 NES GFAP
25 esophageal basaloid squamous cell carcinoma 10.3 TP53 EGFR
26 vulvar seborrheic keratosis 10.3 PTEN CDKN2A
27 papillary ependymoma 10.3 SYP GFAP
28 histiocytic sarcoma 10.3 PTEN CDKN2A
29 vulvar intraepithelial neoplasia 10.3 TP53 CDKN2A
30 breast malignant phyllodes tumor 10.3 TP53 EGFR
31 lung combined type small cell carcinoma 10.3 SYP GFAP
32 mammary analogue secretory carcinoma 10.3 TP53 EGFR
33 malignant peritoneal mesothelioma 10.3 EGFR CDKN2A
34 ovarian seromucinous carcinoma 10.3 TP53 CDKN2A
35 human papillomavirus infectious disease 10.3 TP53 CDKN2A
36 cerebellopontine angle primitive neuroectodermal tumor 10.3 SYP GFAP
37 parkinsonism 10.3
38 anaplastic oligodendroglioma 10.3
39 oligoastrocytoma 10.3
40 overgrowth syndrome 10.3
41 sarcomatoid transitional cell carcinoma 10.3 TP53 SYP
42 bile duct mucinous adenocarcinoma 10.3 TP53 SYP
43 squamous cell papilloma 10.3 TP53 CDKN2A
44 penile benign neoplasm 10.3 TP53 CDKN2A
45 pineocytoma 10.3 SYP GFAP
46 chiari malformation 10.3 SYP GFAP
47 ring chromosome 7 10.3 TP53 MDM2
48 ring chromosome 10.3 TP53 MDM2
49 bizarre leiomyoma 10.3 TP53 CDKN2A
50 tanycytic ependymoma 10.3 SYP GFAP

Graphical network of the top 20 diseases related to Gliomatosis Cerebri:



Diseases related to Gliomatosis Cerebri
Sources

Symptoms & Phenotypes for Gliomatosis Cerebri

About this section

UMLS symptoms related to Gliomatosis Cerebri:


seizures; headache; sensory manifestations

GenomeRNAi Phenotypes related to Gliomatosis Cerebri according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased Hepatitis C Virus pseudoparticles (HCVpp; H77; genotype 1a) infection GR00234-A-1 8.8 BRAF EGFR FGFR4

MGI Mouse Phenotypes related to Gliomatosis Cerebri:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 10.21 BRAF CDKN2A EGFR FGFR4 GFAP IDH1
2 digestive/alimentary MP:0005381 10.13 BRAF CDKN2A EGFR GFAP MDM2 PTEN
3 nervous system MP:0003631 10.1 BRAF CDKN2A EGFR GFAP INA MDM2
4 muscle MP:0005369 10.06 BRAF CDKN2A EGFR GFAP MDM2 PTEN
5 neoplasm MP:0002006 10.03 BRAF CDKN2A EGFR FGFR4 MDM2 PTEN
6 liver/biliary system MP:0005370 10.02 BRAF CDKN2A EGFR MDM2 PTEN RB1
7 normal MP:0002873 10.02 BRAF EGFR GFAP INA MDM2 PTEN
8 limbs/digits/tail MP:0005371 9.97 BRAF EGFR MDM2 PTEN RB1 TP53
9 pigmentation MP:0001186 9.87 BRAF CDKN2A EGFR MDM2 PTEN RB1
10 reproductive system MP:0005389 9.86 BRAF CDKN2A EGFR FGFR4 MDM2 PTEN
11 respiratory system MP:0005388 9.76 BRAF CDKN2A EGFR FGFR4 IDH1 PTEN
12 skeleton MP:0005390 9.61 BRAF CDKN2A EGFR FGFR4 IDH1 MDM2
13 vision/eye MP:0005391 9.23 BRAF CDKN2A EGFR FGFR4 GFAP PTEN
Sources

Drugs & Therapeutics for Gliomatosis Cerebri

About this section

Drugs for Gliomatosis Cerebri (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 71)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Pharmaceutical Solutions Phase 3
2 Psychotropic Drugs Phase 3
3 Anticonvulsants Phase 3
4
Gefitinib Approved, Investigational Phase 1, Phase 2 184475-35-2 123631
5
tannic acid Approved Phase 2 1401-55-4
6
Bevacizumab Approved, Investigational Phase 2 216974-75-3
7
Benzocaine Approved, Investigational Phase 2 1994-09-7, 94-09-7 2337
8
Pembrolizumab Approved Phase 2 1374853-91-4
9
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
10
Valproic acid Approved, Investigational Phase 2 99-66-1 3121
11
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
12 Neurotransmitter Agents Phase 2
13 Antineoplastic Agents, Immunological Phase 2
14 Vaccines Phase 1, Phase 2
15 Angiogenesis Inhibitors Phase 1, Phase 2
16 Adjuvants, Immunologic Phase 1, Phase 2
17 Interleukin-12 Phase 1, Phase 2
18 Antibodies Phase 2
19 Immunoglobulins Phase 2
20 Antibodies, Monoclonal Phase 2
21 Calamus Phase 2
22 Antibiotics, Antitubercular Phase 2
23
Liposomal doxorubicin Phase 2 31703
24 Anti-Bacterial Agents Phase 2
25
Gemcitabine Approved Phase 1 95058-81-4 60750
26
Trametinib Approved Phase 1 871700-17-3 11707110
27
Lenograstim Approved, Investigational Phase 1 135968-09-1
28
Piperazine Approved, Vet_approved Phase 1 110-85-0 4837
29
Palbociclib Approved, Investigational Phase 1 571190-30-2 5005498 5330286 11431660
30
Mebendazole Approved, Vet_approved Phase 1 31431-39-7 4030
31
Dexamethasone Approved, Investigational, Vet_approved Phase 1 50-02-2 5743
32
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 1 1177-87-3
33 Protein Kinase Inhibitors Phase 1
34 Immunologic Factors Phase 1
35 Immunosuppressive Agents Phase 1
36 Anti-Infective Agents Phase 1
37 Antiviral Agents Phase 1
38 Antimetabolites Phase 1
39 Piperazine citrate Phase 1
40 DMP 777 Phase 1 157341-41-8
41 Antineoplastic Agents, Hormonal Phase 1
42 Gastrointestinal Agents Phase 1
43 Antiemetics Phase 1
44 Hormone Antagonists Phase 1
45 Hormones Phase 1
46 glucocorticoids Phase 1
47 BB 1101 Phase 1
48 Anti-Inflammatory Agents Phase 1
49
Dopamine Approved 62-31-7, 51-61-6 681
50
Etoposide Approved Early Phase 1 33419-42-0 36462

Interventional clinical trials:

(show all 17)
# Name Status NCT ID Phase Drugs
1 International Cooperative Phase III Trial of the HIT-HGG Study Group for the Treatment of High Grade Glioma, Diffuse Intrinsic Pontine Glioma, and Gliomatosis Cerebri in Children and Adolescents < 18 Years.(HIT-HGG-2013) Recruiting NCT03243461 Phase 3 Temozolomide + Valproic Acid
2 Phase I/II Trial of Gefitinib and Radiation in Pediatric Patients Newly Diagnosed With Brain Stem Tumors or Incompletely Resected Supratentorial Malignant Gliomas With Phase II Limited to Brain Stem Tumors Completed NCT00042991 Phase 1, Phase 2 gefitinib
3 A Phase 2 Study of Valproic Acid and Radiation, Followed by Maintenance Valproic Acid and Bevacizumab in Children With Newly Diagnosed High-grade Gliomas or Brainstem Gliomas Completed NCT00879437 Phase 2 Valproic acid;Bevacizumab
4 Clinical Study of an Dendritic and Glioma Cells Fusion Vaccine With IL-12 for Treatment-naïve GBM Patients. Recruiting NCT04388033 Phase 1, Phase 2 Interleukin-12;Temozolomide
5 A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192) Active, not recruiting NCT02798406 Phase 2
6 An Open-label, Single-arm, Phase II Study to Evaluate Safety and Efficacy of Doxorubicin in Combination With Radiotherapy, Temozolomide and Valproic Acid in Patients With Glioblastoma Multiforme (GBM) and Diffuse Intrinsic Pontine Glioma (DIPG) Terminated NCT02758366 Phase 2 Doxorubicin
7 An Open-Label, Dose Escalation, Efficacy, and Safety Study of CLR 131 in Children, Adolescents, and Young Adults With Select Solid Tumors, Lymphoma, and Malignant Brain Tumors Recruiting NCT03478462 Phase 1 CLR 131
8 Phase 1 Trial of Engineered HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors Recruiting NCT03911388 Phase 1
9 A First-in-human Phase I Single-agent Dose-escalation, Food Effect and Dose Expansion Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms Recruiting NCT04541082 Phase 1 ONC206
10 Molecularly-Driven Doublet Therapy for All Children With Refractory or Recurrent CNS Malignant Neoplasms and Young Adults With Refractory or Recurrent SHH Medulloblastoma Recruiting NCT03434262 Phase 1 Gemcitabine;ribociclib;sonidegib;trametinib
11 Phase I Study of CDK 4-6 Inhibitor PD-0332991 (Palbociclib; IBRANCE) in Children With Recurrent, Progressive or Refractory Central Nervous System Tumors Terminated NCT02255461 Phase 1 palbociclib isethionate
12 A Phase I Study of Intratumoral/Peritumoral Herpes Simplex Virus-1 Mutant HSV1716 in Patients With Refractory or Recurrent High Grade Gliomas (HGG) Terminated NCT02031965 Phase 1 dexamethasone
13 Untersuchungen Zur Verlaufskontrolle Bei Re-Bestrahlung Von Glioblastompatienten Mittels Kombinierter [18F]FET-PET-Kernspintomographie Unknown status NCT01579253
14 Molecular-guided Therapy for the Treatment of Patients With Relapsed and Refractory Childhood Cancers Active, not recruiting NCT02162732
15 18F-FDOPA PET/CT or PET/MRI in Patients With Gliomas Terminated NCT02175745 18F-fluoro-dihydroxyphenylalanine
16 A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors Terminated NCT02653196 Early Phase 1 Keratinocyte Growth Factor;Alemtuzumab;Thiotepa;Etoposide;Fludarabine;Melphalan;Tacrolimus;Cyclosporine A;Mycophenolate mofetil
17 Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors Withdrawn NCT02194452

Search NIH Clinical Center for Gliomatosis Cerebri

Cochrane evidence based reviews: neoplasms, neuroepithelial

Sources

Genetic Tests for Gliomatosis Cerebri

About this section
Sources

Anatomical Context for Gliomatosis Cerebri

About this section

MalaCards organs/tissues related to Gliomatosis Cerebri:

40
Brain, Eye, Spinal Cord, Cerebellum, Breast, Temporal Lobe, Pituitary
Sources

Publications for Gliomatosis Cerebri

About this section

Articles related to Gliomatosis Cerebri:

(show top 50) (show all 383)
# Title Authors PMID Year
1
Clinicopathological study of cellular proliferation and invasion in gliomatosis cerebri: important role of neural cell adhesion molecule L1 in tumour invasion. 54 61
15677537 2005
2
Analysis of TP53 and PTEN in gliomatosis cerebri. 61 54
12734658 2003
3
Assessment of proliferative potential in gliomatosis cerebri. 54 61
1856741 1991
4
Canine Gliomatosis Cerebri: Morphologic and Immunohistochemical Characterization Is Supportive of Glial Histogenesis. 61
33357125 2021
5
Analysis of preventability of malignancy-related maternal death from the nationwide registration system of maternal deaths in Japan. 61
30999803 2021
6
Fluctuation of Clinical Signs With Near-Syncopal Episodes in a Dog With Gliomatosis Cerebri: A Diagnostic Challenge. 61
33434679 2021
7
Gliomatosis Cerebri Growth Pattern: Association of Differential First-Line Treatment with Overall Survival in WHO Grade II and III Gliomas. 61
33472203 2021
8
Predictive factors for overall survival in surgical cases of gliomatosis cerebri from the National Cancer Database. 61
33222914 2020
9
A pediatric case of anaplastic astrocytoma with a gliomatosis cerebri; the growth pattern and changes in serum VEGF-121 levels after bevacizumab treatment. 61
33222957 2020
10
Gliomatosis cerebri mimicking diffuse demyelinating disease: Case Report. 61
32742528 2020
11
A phase I trial of lenalidomide and radiotherapy in children with diffuse intrinsic pontine gliomas or high-grade gliomas. 61
33040274 2020
12
A case of pediatric gliomatosis cerebri harboring H3F3A K27 mutation. 61
32965767 2020
13
Multimodal neuroimaging of gliomatosis cerebri: a case series of four patients. 61
32913666 2020
14
Gliomatosis cerebri (GC) or GC-like? A picture to be reconsidered in neuro-oncology based on large retrospective analysis of GC series. 61
32114667 2020
15
Gliomatosis cerebri and Rasmussen's encephalitis: Two different entities causing refractory epilepsy. Comparison through two clinical cases. 61
32439411 2020
16
Outcomes of presumed malignant glioma treated without pathological confirmation: a retrospective, single-center analysis. 61
33282325 2020
17
Mortal consequences of a cooperative action between Takotsubo syndrome and increased intracranial pressure. 61
32142222 2020
18
Clinical relevance of molecular subgrouping of gliomatosis cerebri per 2016 WHO classification: a clinicopathological study of 89 cases. 61
31435963 2020
19
Adult H3K27M-mutant diffuse midline glioma with gliomatosis cerebri growth pattern: Case report and review of the literature. 61
32145563 2020
20
Imaging characteristics of adult H3 K27M-mutant gliomas. 61
31731269 2019
21
Radiological Characteristics and Natural History of Adult IDH-Wildtype Astrocytomas with TERT Promoter Mutations. 61
30407589 2019
22
Corticosteroid-induced immunodeficiency in a patient with gliomatosis cerebri: Are corticosteroids indicated in all brain tumors? 61
30964431 2019
23
Gliomatosis Cerebri: A Unique Presentation with Accompanying Clinical Nuance. 61
31528509 2019
24
Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors. 61
31025086 2019
25
Gliomatosis Cerebri Among Children and Adolescents: An Individual-Patient Data Meta-analysis of 182 Patients. 61
30887873 2019
26
[Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors. German version]. 61
30790013 2019
27
Heterogeneity of glioblastoma with gliomatosis cerebri growth pattern on diffusion and perfusion MRI. 61
30565029 2019
28
Wide Range of Clinical Outcomes in Patients with Gliomatosis Cerebri Growth Pattern: A Clinical, Radiographic, and Histopathologic Study. 61
30097523 2019
29
An autopsy case of widespread brain dissemination of glioblastoma unnoticed by magnetic resonance imaging after treatment with bevacizumab. 61
31528472 2019
30
Prognostic Factors and Survival of Gliomatosis Cerebri: A Systematic Review and Meta-Analysis. 61
30172970 2018
31
An Adolescent Presenting With Seizures as a Symptom of Gliomatosis Cerebri. 61
28486262 2018
32
Clinical, neuroimaging and histopathological features of gliomatosis cerebri: a systematic review based on synthesis of published individual patient data. 61
30117023 2018
33
Gliomatosis cerebri: a consensus summary report from the Second International Gliomatosis cerebri Group Meeting, June 22-23, 2017, Bethesda, USA. 61
29998396 2018
34
Incidence and survival of gliomatosis cerebri: a population-based cancer registration study. 61
29464663 2018
35
Magnetic resonance imaging features of canine gliomatosis cerebri. 61
29110365 2018
36
WHO 2016 Classification of gliomas. 61
28815663 2018
37
Lactoferrin- and RGD-comodified, temozolomide and vincristine-coloaded nanostructured lipid carriers for gliomatosis cerebri combination therapy. 61
29861635 2018
38
Astroblastoma - reviewing literature and one case report. 61
30845307 2018
39
Gliomatosis Cerebri: A Rare Brain Tumor. 61
29459616 2018
40
Feline glioma: a retrospective study and review of the literature. 61
28156189 2017
41
A Pediatric Case of Diffuse Glioma Diagnosed at Autopsy. 61
31240015 2017
42
2016 Updates to the WHO Brain Tumor Classification System: What the Radiologist Needs to Know. 61
29028423 2017
43
Positive influence of partial resection on overall survival of patients with overlapping glioblastomas. 61
28837843 2017
44
Gliomatosis cerebri: Prognosis based on current molecular markers. 61
28539209 2017
45
The usefulness of 18F-fluorocholine PET/CT in the detection of recurrence of central nervous system primary neoplasms. 61
28219644 2017
46
Management and Survival Patterns of Patients with Gliomatosis Cerebri: A SEER-Based Analysis. 61
28366748 2017
47
Prevalence and clinicopathological features of H3.3 G34-mutant high-grade gliomas: a retrospective study of 411 consecutive glioma cases in a single institution. 61
28447171 2017
48
Molecular alterations in pediatric gliomatosis cerebri are similar to those in less invasive forms of pediatric diffuse glioma. 61
28421462 2017
49
Gliomatosis cerebri in a 10-year-old male patient. 61
28484570 2017
50
Changes in cerebral metabolism during ketogenic diet in patients with primary brain tumors: 1H-MRS study. 61
28074323 2017
Sources

Variations for Gliomatosis Cerebri

About this section

ClinVar genetic disease variations for Gliomatosis Cerebri:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 APC NM_000038.6(APC):c.7402T>C (p.Ser2468Pro) SNV Uncertain significance 184474 rs375586273 GRCh37: 5:112178693-112178693
GRCh38: 5:112842996-112842996
Sources

Expression for Gliomatosis Cerebri

About this section
Search GEO for disease gene expression data for Gliomatosis Cerebri.
Sources

Pathways for Gliomatosis Cerebri

About this section

Pathways related to Gliomatosis Cerebri according to GeneCards Suite gene sharing:

(show top 50) (show all 56)
# Super pathways Score Top Affiliating Genes
1
ERK Signaling 63
Show member pathways
 13.77 TP53 RB1 PTEN MDM2 FGFR4 EGFR
2
GPCR Pathway 63
Show member pathways
 13.64 TP53 RB1 MDM2 FGFR4 EGFR CDKN2A
3
Phospholipase-C Pathway 63
Show member pathways
 13.02 TP53 PTEN MDM2 FGFR4 EGFR BRAF
4
PI3K-Akt signaling pathway 36
Show member pathways
 12.95 TP53 RB1 PTEN MDM2 FGFR4 EGFR
5
Human cytomegalovirus infection 36
Show member pathways
 12.9 TP53 RB1 MDM2 EGFR CDKN2A
6
Endometrial cancer 36
Show member pathways
 12.75 TP53 RB1 PTEN MDM2 EGFR CDKN2A
7
Downstream signaling events of B Cell Receptor (BCR) 65
Show member pathways
 12.69 TP53 PTEN MDM2 FGFR4 EGFR
8
Gastric cancer 36
Show member pathways
 12.69 TP53 RB1 PTEN EGFR CDKN2A BRAF
9
4-1BB Pathway 63
Show member pathways
 12.61 TP53 RB1 EGFR BRAF
10
ErbB signaling pathway 36 1
Show member pathways
 12.59 TP53 PTEN MDM2 EGFR BRAF
11
Glioma 36
Show member pathways
 12.58 TP53 RB1 PTEN MDM2 EGFR CDKN2A
12
Pathways in cancer 36
12.58 TP53 RB1 PTEN MDM2 FGFR4 EGFR
13
Mitotic G1-G1/S phases 65
Show member pathways
 12.53 TP53 RB1 MDM2 CDKN2A
14
MicroRNAs in cancer 36
12.5 TP53 PTEN MDM2 EGFR CDKN2A
15
DNA Damage 4
12.48 TP53 RB1 MDM2 CDKN2A
16
mTOR signaling pathway (KEGG) 36
Show member pathways
 12.46 TP53 PTEN FGFR4 EGFR BRAF
17
VEGF Signaling 66
Show member pathways
 12.45 TP53 PTEN MDM2 FGFR4 EGFR
18
Apoptosis Pathway 69
Show member pathways
 12.42 TP53 MDM2 FGFR4 EGFR
19
Cell cycle 36 1
12.34 TP53 RB1 MDM2 CDKN2A
20
DNA Damage Response 1
Show member pathways
 12.34 TP53 RB1 PTEN MDM2 CDKN2A
21
Human T-cell leukemia virus 1 infection 36
12.32 TP53 RB1 PTEN CDKN2A
22
Translation Non-genomic (rapid) action of Androgen Receptor 23
Show member pathways
 12.3 TP53 PTEN MDM2 EGFR
23
Proteoglycans in cancer 36
12.29 TP53 MDM2 EGFR BRAF
24
Viral carcinogenesis 36
12.28 TP53 RB1 MDM2 CDKN2A
25
p53 Signaling 63
Show member pathways
 12.23 TP53 RB1 PTEN MDM2
26
Immune response IFN alpha/beta signaling pathway 23
Show member pathways
 12.22 TP53 RB1 FGFR4 EGFR
27
Cellular senescence (KEGG) 36
12.12 TP53 RB1 PTEN MDM2 CDKN2A
28
MAPK Signaling: Mitogen Stimulation Pathway 64
Show member pathways
 12.1 TP53 RB1 PTEN MDM2 FGFR4 EGFR
29
FoxO signaling pathway 36
Show member pathways
 12.07 PTEN MDM2 EGFR BRAF
30
Spinal Cord Injury 1
12 TP53 RB1 GFAP EGFR
31
Direct p53 effectors 1
12 TP53 RB1 PTEN MDM2 EGFR
32
MAPK Pathway 69
Show member pathways
 11.99 TP53 EGFR BRAF
33
Integrated Breast Cancer Pathway 1
11.99 TP53 RB1 PTEN MDM2 EGFR BRAF
34
DNA Damage Response (only ATM dependent) 1
11.97 TP53 PTEN MDM2 CDKN2A
35
Signaling by ERBB4 65
Show member pathways
 11.92 MDM2 GFAP EGFR
36
Cytoskeleton remodeling Neurofilaments 23
Show member pathways
 11.92 NES INA GFAP
37
Small cell lung cancer 36
11.84 TP53 RB1 PTEN
38
Androgen receptor signaling pathway 1
11.84 RB1 PTEN MDM2 EGFR
39
Retinoblastoma (RB) in Cancer 1
11.82 TP53 RB1 MDM2
40
Neural Stem Cell Differentiation Pathways and Lineage-specific Markers 64
11.76 SYP NES GFAP FGFR4
41
Regulation of TP53 Expression and Degradation 65
Show member pathways
 11.73 TP53 MDM2 CDKN2A
42
Platinum drug resistance 36
11.73 TP53 MDM2 CDKN2A
43
Pathways Affected in Adenoid Cystic Carcinoma 1
11.68 TP53 PTEN FGFR4
44
Transcription_P53 signaling pathway 23
11.68 TP53 RB1 MDM2 CDKN2A
45
Central carbon metabolism in cancer 36
11.68 TP53 PTEN IDH1 EGFR
46
Senescence and Autophagy in Cancer 1
11.66 TP53 RB1 PTEN MDM2 CDKN2A BRAF
47
HIF1Alpha Pathway 63
11.57 TP53 MDM2 CDKN2A
48
Copper homeostasis 1
11.57 TP53 PTEN MDM2
49
Photodynamic therapy-induced AP-1 survival signaling. 1
11.52 TP53 RB1 EGFR CDKN2A
50
Integrated Cancer Pathway 1
11.46 TP53 RB1 PTEN MDM2
Sources

GO Terms for Gliomatosis Cerebri

About this section

Cellular components related to Gliomatosis Cerebri according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 PML body GO:0016605 8.8 TP53 RB1 PTEN

Biological processes related to Gliomatosis Cerebri according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 9.95 TP53 RB1 PTEN MDM2 CDKN2A
2 negative regulation of apoptotic process GO:0043066 9.88 TP53 PTEN MDM2 EGFR BRAF
3 peptidyl-tyrosine phosphorylation GO:0018108 9.79 FGFR4 EGFR BRAF
4 response to organic cyclic compound GO:0014070 9.79 PTEN IDH1 EGFR
5 cell cycle arrest GO:0007050 9.78 TP53 RB1 CDKN2A
6 cellular response to hypoxia GO:0071456 9.77 TP53 PTEN MDM2
7 response to oxidative stress GO:0006979 9.76 TP53 IDH1 EGFR
8 negative regulation of cell growth GO:0030308 9.75 TP53 RB1 CDKN2A
9 Ras protein signal transduction GO:0007265 9.69 TP53 RB1 CDKN2A
10 negative regulation of neuron projection development GO:0010977 9.67 PTEN MDM2 GFAP
11 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.62 PTEN FGFR4 EGFR BRAF
12 positive regulation of cardiac muscle cell apoptotic process GO:0010666 9.59 TP53 PTEN
13 cellular response to drug GO:0035690 9.58 TP53 EGFR BRAF
14 replicative senescence GO:0090399 9.57 TP53 CDKN2A
15 cardiac septum morphogenesis GO:0060411 9.56 TP53 MDM2
16 amyloid fibril formation GO:1990000 9.54 MDM2 CDKN2A
17 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.54 RB1 PTEN CDKN2A
18 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.52 TP53 EGFR
19 cellular response to UV-C GO:0071494 9.46 TP53 MDM2
20 regulation of axon regeneration GO:0048679 9.43 PTEN BRAF
21 long-term synaptic potentiation GO:0060291 9.43 PTEN GFAP BRAF
22 cellular response to actinomycin D GO:0072717 9.16 TP53 MDM2
23 negative regulation of mitotic cell cycle GO:0045930 9.13 TP53 RB1 EGFR
24 positive regulation of gene expression GO:0010628 9.1 TP53 PTEN MDM2 FGFR4 CDKN2A BRAF

Molecular functions related to Gliomatosis Cerebri according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ubiquitin protein ligase binding GO:0031625 9.67 TP53 RB1 MDM2 EGFR
2 protein tyrosine kinase activity GO:0004713 9.63 FGFR4 EGFR BRAF
3 enzyme binding GO:0019899 9.63 TP53 RB1 PTEN MDM2 LUC7L2 EGFR
4 identical protein binding GO:0042802 9.61 TP53 SYP RB1 PTEN MDM2 IDH1
5 kinase binding GO:0019900 9.58 RB1 GFAP EGFR
6 SUMO transferase activity GO:0019789 9.43 MDM2 CDKN2A
7 p53 binding GO:0002039 9.43 TP53 MDM2 CDKN2A
8 MDM2/MDM4 family protein binding GO:0097371 9.32 TP53 CDKN2A
9 disordered domain specific binding GO:0097718 8.92 TP53 RB1 MDM2 CDKN2A
Sources

Sources for Gliomatosis Cerebri

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....